Scholarlink

Purpose <p>Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (RPT) is an established treatment for advanced prostate cancer, but renal radiation exposure remains a major safety concern, as no clinically established nephroprotective strategy exists. Preclinical data suggest metformin to reduce renal radiopharmaceutical retention by interfering with tubular reabsorption. This study aimed to investigate the effect of metformin on renal and tumor dosimetry in PSMA RPT patients.</p> Methods <p>57 patients undergoing PSMA RPT were retrospectively analyzed (n=15 with metformin; n=42 without metformin). The mean kidney absorbed dose (AD) and mean tumor AD (up to three randomly selected osseous metastases per patient) were assessed by post-RPT dosimetry. Total tumor volume (TTV) was evaluated as a potential confounder. </p> Results <p>Patients on metformin showed a significantly lower mean kidney AD compared to patients without metformin (median 0.290 vs. 0.367 Gy/GBq; p=0.046). In multiple linear regression analysis, metformin use was independently associated with reduced mean kidney AD, whereas TTV was not a significant predictor. No significant difference in mean tumor AD was observed between groups (0.739 vs. 0.997 Gy/GBq; p=0.215), indicating preserved tumor targeting. No association between tumor burden and mean kidney AD was detected, suggesting independence from tumor sink effect.</p> Conclusion <p>Metformin use was associated with a reduced mean kidney AD in patients undergoing PSMA RPT without affecting tumor ADs. Thus, metformin may represent a promising and widely available strategy to reduce renal radiation exposure and improve the therapeutic index of PSMA-targeted RPT. Prospective studies are warranted to validate these findings and define optimal treatment regimens.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry

  • 期刊论文

  • 发表日期：

    2026年6月26日

查看全文
  • Sophie Carina Siegmund,
  • Astrid Delker,
  • Liam Widjaja,
  • Johannes Hornfeck,
  • Muyu Wu,
  • Lena M. Unterrainer,
  • Franz Josef Gildehaus,
  • Guido Böning,
  • Rudolf A. Werner,
  • Zachary Ells

摘要

Purpose

Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (RPT) is an established treatment for advanced prostate cancer, but renal radiation exposure remains a major safety concern, as no clinically established nephroprotective strategy exists. Preclinical data suggest metformin to reduce renal radiopharmaceutical retention by interfering with tubular reabsorption. This study aimed to investigate the effect of metformin on renal and tumor dosimetry in PSMA RPT patients.

Methods

57 patients undergoing PSMA RPT were retrospectively analyzed (n=15 with metformin; n=42 without metformin). The mean kidney absorbed dose (AD) and mean tumor AD (up to three randomly selected osseous metastases per patient) were assessed by post-RPT dosimetry. Total tumor volume (TTV) was evaluated as a potential confounder.

Results

Patients on metformin showed a significantly lower mean kidney AD compared to patients without metformin (median 0.290 vs. 0.367 Gy/GBq; p=0.046). In multiple linear regression analysis, metformin use was independently associated with reduced mean kidney AD, whereas TTV was not a significant predictor. No significant difference in mean tumor AD was observed between groups (0.739 vs. 0.997 Gy/GBq; p=0.215), indicating preserved tumor targeting. No association between tumor burden and mean kidney AD was detected, suggesting independence from tumor sink effect.

Conclusion

Metformin use was associated with a reduced mean kidney AD in patients undergoing PSMA RPT without affecting tumor ADs. Thus, metformin may represent a promising and widely available strategy to reduce renal radiation exposure and improve the therapeutic index of PSMA-targeted RPT. Prospective studies are warranted to validate these findings and define optimal treatment regimens.